FAST Study Follow Up study participation - FASTER
What is it?
Active participation in the FAST study ended with the last patient visit undertaken by the 31st of December 2019. We hope to publish the results of the study towards the end of 2020. In addition to this main study, we would like to continue to keep in contact with you in order to understand the longer-term effects of the medicines used in the FAST trial on your cardiovascular health. This will inform patients and doctors in the future about the safe and effective use of these medications.
We are planning a new study, called the FASTER – FAST Extended Review. This would involve us sending you a questionnaire to complete every 5 years or so. We would also request access to your electronic health information from the NHS to review any significant medical events that you may have (this is called record linkage). This new study will be an observational study, which means it will not involve you taking any study medication, or attending any study appointments.
Why would you want me?
Your participation in the FAST study has already been extremely valuable in terms of studying the relative safety of febuxostat and allopurinol, and we hope to be able to build on this research by following your health in the longer term.
What would I have to do?
This long-term FAST follow-up study is currently in the planning stage. The study would not involve you taking medication, but we would like to send you a questionnaire periodically and also be able to access your medical records to find out about your cardiovascular health including any hospital admissions.
At this stage we are asking if you would be willing to be contacted about it once it has been approved by the ethics committee. If you would like to be contacted with further information about this study, please complete the form below.
There is no obligation to take part and you will be free to stop taking part at any time.